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ARG1

:   arginase 1

BP

:   biological process

CC

:   cellular component

COPD

:   chronic obstructive pulmonary disease

CS

:   cigarette smoke

CX3CR1

:   C‐X3‐C motif chemokine receptor 1

DALY

:   disability‐adjusted life year

DEG

:   differentially expressed gene

EGR1

:   early growth response 1

FC

:   fold change

FGG

:   fibrinogen gamma chain

FPR1

:   formyl peptide receptor 1

FPR2

:   formyl peptide receptor 2

GO

:   Gene Ontology

GS

:   gene significance

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

MF

:   molecular function

MM

:   module membership

ORM1

:   orosomucoid 1

PPBP

:   proplatelet basic protein

PPI

:   protein‐protein interaction

PTGS2

:   prostaglandin‐endoperoxide synthase 2

S100A12

:   S100 calcium binding protein A12

S100A8

:   S100 calcium binding protein A8

S100A9

:   S100 calcium binding protein A9

VCAM1

:   vascular cell adhesion molecule 1

[wgcna]{.smallcaps}

:   weighted gene coexpression network analysis

YLLs

:   years of life lost

Chronic obstructive pulmonary disease (COPD), characterized by long‐term poorly reversible airway limitation and persistent respiratory symptoms, is a common and preventable disease [1](#feb412719-bib-0001){ref-type="ref"}. COPD is projected to become the third leading cause of all death by 2030 in the world [2](#feb412719-bib-0002){ref-type="ref"}. Globally, COPD affected 299.4 million people in 2017, with a 71.2% increase in the prevalence rate compared with 2015, ranking it as the fifth leading cause of disability‐adjusted life years (DALYs) and the seventh leading noncommunicable disease cause of years of life lost (YLLs) [3](#feb412719-bib-0003){ref-type="ref"}, [4](#feb412719-bib-0004){ref-type="ref"}, [5](#feb412719-bib-0005){ref-type="ref"}, [6](#feb412719-bib-0006){ref-type="ref"}. As shown in Fig. [1](#feb412719-fig-0001){ref-type="fig"}A, we observed a 12.3% increase in global all‐age deaths caused by COPD from 2.85 million in 1990 to 3.20 million in 2017 [6](#feb412719-bib-0006){ref-type="ref"}, [7](#feb412719-bib-0007){ref-type="ref"}, [8](#feb412719-bib-0008){ref-type="ref"}, [9](#feb412719-bib-0009){ref-type="ref"} and a predicted increase of 60% by 2020 compared with 1990. Figure [1](#feb412719-fig-0001){ref-type="fig"}B indicated that the all‐age standardized death rate of COPD in males, females, and both sexes separately decreased from 1990 to 2015 [6](#feb412719-bib-0006){ref-type="ref"}, [8](#feb412719-bib-0008){ref-type="ref"}, which could be because of population growth and aging. Although the COPD death rate varies with different countries, more than 90% of COPD deaths occurred in low‐ and middle‐income countries [10](#feb412719-bib-0010){ref-type="ref"}. The global all‐age YLLs with COPD showed a small increase of 7.5% and 3.6% for both sexes and males, respectively, as well as a 21% decrease for females from 1990 to 2015 (Fig. [1](#feb412719-fig-0001){ref-type="fig"}C) [6](#feb412719-bib-0006){ref-type="ref"}, [8](#feb412719-bib-0008){ref-type="ref"}. In addition, as shown in Fig. [1](#feb412719-fig-0001){ref-type="fig"}D [3](#feb412719-bib-0003){ref-type="ref"}, [4](#feb412719-bib-0004){ref-type="ref"}, [5](#feb412719-bib-0005){ref-type="ref"}, [7](#feb412719-bib-0007){ref-type="ref"}, [11](#feb412719-bib-0011){ref-type="ref"}, [12](#feb412719-bib-0012){ref-type="ref"}, [13](#feb412719-bib-0013){ref-type="ref"}, [14](#feb412719-bib-0014){ref-type="ref"}, global all‐age DALYs caused by COPD had a small increase of 4.2% during 1990--2015 and was projected to decline to 57.6 million by 2020. The age‐standardized DALY rate caused by COPD in females was about twice as high as that of males, and that in low‐ and middle‐income countries was 6.7 times higher than in some high‐income countries [3](#feb412719-bib-0003){ref-type="ref"}. We observed that the global all‐age years lived with disability caused by COPD has grown 52.2% from 1990 to 2017. Taken together, COPD has presented a global public health challenge with high prevalence, mortality and disability rates, whereas the diagnosis of COPD is usually made based on spirometry values and clinical symptoms with a frequent underdiagnosis [15](#feb412719-bib-0015){ref-type="ref"}. Thus, it is important to explore the underlying molecular mechanisms and identify more effective early diagnostic methods and reliable biomarkers for this disease.

![The global death and burden caused by COPD. (A) Global age‐related deaths (millions) caused by COPD in men and women, respectively, from 1990 to 2020 [6](#feb412719-bib-0006){ref-type="ref"}, [7](#feb412719-bib-0007){ref-type="ref"}, [8](#feb412719-bib-0008){ref-type="ref"}, [9](#feb412719-bib-0009){ref-type="ref"}. (B) Global age‐related death rates (per 100 000) caused by COPD for both sexes, males and females, respectively, from 1990 to 2015 [6](#feb412719-bib-0006){ref-type="ref"}, [8](#feb412719-bib-0008){ref-type="ref"}. (C) Global age‐related YLLs (millions) caused by COPD for both sexes, males and female, respectively, from 1990 to 2015 [6](#feb412719-bib-0006){ref-type="ref"}, [8](#feb412719-bib-0008){ref-type="ref"}. (D) Global age‐related DALYs and years lived with disability (YLD) (millions) by COPD for both sexes from 1990 to 2020 [3](#feb412719-bib-0003){ref-type="ref"}, [4](#feb412719-bib-0004){ref-type="ref"}, [5](#feb412719-bib-0005){ref-type="ref"}, [7](#feb412719-bib-0007){ref-type="ref"}, [11](#feb412719-bib-0011){ref-type="ref"}, [12](#feb412719-bib-0012){ref-type="ref"}, [13](#feb412719-bib-0013){ref-type="ref"}, [14](#feb412719-bib-0014){ref-type="ref"}.](FEB4-9-1880-g001){#feb412719-fig-0001}

As a large‐scale and efficient technique for acquiring genomic data, microarray‐based gene expression profiles have been widely used to seek new insights for biomarkers in many human diseases [16](#feb412719-bib-0016){ref-type="ref"}. Currently, many studies have been conducted on COPD gene expression profiles, and these studies have screened thousands of differentially expressed genes (DEGs) implicated in the development and progression of this disease [17](#feb412719-bib-0017){ref-type="ref"}, [18](#feb412719-bib-0018){ref-type="ref"}. However, the results for the identification of DEGs are discrepant among these studies due to sample heterogeneity and differences in technological detection platforms. In this study, we performed an integrated analysis on some of the gene expression profiling data based on lung tissues of COPD cases and control subjects using an unbiased approach aiming to identify the potential molecular mechanisms and biomarkers for COPD.

We selected two Gene Expression Omnibus microarray datasets on COPD ( [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986)). DEGs were identified by [r]{.smallcaps} software (Auckland, New Zealand) and subsequently analyzed using bioinformatic methods including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichments and construction of protein‐protein interaction (PPI) and weighted gene coexpression analysis ([wgcna]{.smallcaps}) networks. We screened the DEGs for potential association with the development and progression of COPD. Our work may further the understanding of the potential molecular mechanisms of COPD.

Materials and methods {#feb412719-sec-0002}
=====================

Gene data {#feb412719-sec-0003}
---------

Two gene expression datasets, [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986), were downloaded from the National Center for Biotechnology Information Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/). [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) comprises the expression profile from 64 lung tissue samples from COPD cases and 16 samples from healthy donors [19](#feb412719-bib-0019){ref-type="ref"}. [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986) includes molecular profiling of 19 lung tissue samples, containing 14 samples from COPD cases and 5 from smokers [20](#feb412719-bib-0020){ref-type="ref"}. The experiments of [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986) were conducted on the Affymetrix Human Exon 1.0 ST GeneChip (Affymetrix, Inc., Santa Clara, CA, USA; GPL5175 platform) and Agilent‐026652 Whole Human Genome Microarray 4x44K v2 (Agilent Technologies, Inc., Palo Alto, CA, USA; GPL13497 platform), respectively.\#AuthorQuery Rep

Data preprocessing and screening for DEGs {#feb412719-sec-0004}
-----------------------------------------

The probe set IDs of two datasets were converted into gene symbols using the [r]{.smallcaps} software and annotation packages. The two datasets were merged into one array dataset and then batch normalized using [r]{.smallcaps} packages (sva and limma 3.40.6). The DEGs between COPD cases and control subjects were identified using the limma package in [r]{.smallcaps} 3.60. A *P*‐value \<0.05 after being adjusted by false discovery rate and \|log2FC \> 1, where FC represents fold change, were applied together as the cutoff for DEGs screening.

GO and KEGG pathway enrichment analysis of DEGs {#feb412719-sec-0005}
-----------------------------------------------

GO enrichment of the DEGs on the biological process (BP), molecular function (MF) and cellular component (CC) categories was performed using a [david]{.smallcaps} online tool (<https://david.ncifcrf.gov/>) [21](#feb412719-bib-0021){ref-type="ref"}, [22](#feb412719-bib-0022){ref-type="ref"}. KEGG pathway enrichment analysis was performed by using the KOBAS 3.0 online analysis database (<http://kobas.cbi.pku.edu.cn/>) [23](#feb412719-bib-0023){ref-type="ref"}.

Construction of the PPI network {#feb412719-sec-0006}
-------------------------------

STRING database (<https://string-db.org/>) is frequently used for identifying the protein interactions [16](#feb412719-bib-0016){ref-type="ref"}, [24](#feb412719-bib-0024){ref-type="ref"}. STRING database contains huge amounts of experimental and text mining data [25](#feb412719-bib-0025){ref-type="ref"}. [cytoscape]{.smallcaps} is an open source bioinformatic software platform used for integrating gene expression profiles and visualizing molecular interaction networks. [cytoscape]{.smallcaps} plugin cytoHubba provides multiple topological analysis methods on Hub genes, regulatory networks and drug targets for experimental biologists [26](#feb412719-bib-0026){ref-type="ref"}. In this study, we used STRING database to identify the interactions between the identified DEGs. A confidence score \>0.4 was used as the cutoff criterion. In addition, Hub DEGs were identified with [cytoscape]{.smallcaps} version 3.6.1 (1999 Free Software Foundation, Inc., Boston, MA, USA) with cytoHubba plugin according to the rank of connection degree (number) for each gene, which is represented by the different degrees of color (from red to yellow): the role of the gene is greater in the PPI network with the darker color of the gene [26](#feb412719-bib-0026){ref-type="ref"}.

[wgcna]{.smallcaps} on COPD {#feb412719-sec-0007}
---------------------------

[wgcna]{.smallcaps} may be used for screening modules (clusters) of highly correlated genes and for calculating module membership (MM) measures, in which the module eigengene or an intramodular Hub gene is used to summarize such modules, and eigengene network methodology is used for relating modules to one another and to external sample traits [27](#feb412719-bib-0027){ref-type="ref"}. In this study, the [wgcna]{.smallcaps} package was used to identify coexpression modules for the merged and standardized array datasets ([GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986)). In brief, first, a weighted adjacency matrix containing pairwise connection strengths was constructed based on the selected soft threshold power (β = 11) on the matrix of pairwise correlation coefficients. Then, the connectivity measure per gene was calculated by summing the connection strengths with other genes; modules were defined as branches of a hierarchical clustering tree by using a dissimilarity measure, and each module was assigned a color. Subsequently, module preservation [r]{.smallcaps} function was used to assess the module structure preservation. Finally, the module eigengene was used for summarizing the gene expression profiles of each module, and each module eigengene was regressed on case trait (COPD) and smoking status by using the linear model in the limma [r]{.smallcaps} package.

Results {#feb412719-sec-0008}
=======

Identification of DEGs in COPD {#feb412719-sec-0009}
------------------------------

After batch normalization on the integrated dataset from [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986) by the sva and limma packages, 139 DEGs were identified using the limma package (corrected *P* \< 0.05; \|log2FC\| \> 1) (Tables [1](#feb412719-tbl-0001){ref-type="table"} and [2](#feb412719-tbl-0002){ref-type="table"}). The cluster heatmap of the top 139 DEGs is shown in Fig. [2](#feb412719-fig-0002){ref-type="fig"}. Among them, 62 genes were up‐regulated and 77 genes were down‐regulated, which is shown in Fig. [3](#feb412719-fig-0003){ref-type="fig"}.

###### 

Screening up‐regulated and down‐regulated DEGs in COPD by integrated microarray

  DEGs                        Gene symbol
  --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Up‐regulated (62 genes)     *PIEZO2*,*INHBA*,*VCAM1*,*RSPO2*,*CD1C*,*HSD17B6*,*AQP3*,*APLNR*,*GPD1*,*EGR2*,*KCNA*,*SLC18A2*,*FRZB*,*PTGS2*,*OLR1*,*EDNRA*,*SHISA2*,*ELF5*,*LUM*,*CYSLTR1*,*BMP5*,*HPGDS*,*MS4A2*,*DCC*,*FOSB*,*HHIP*,*MSMB*,*CD200*,*AMPD1*,*ICOS*,*RTKN2*,*CD83*,*FABP4*,*ISLR*,*GPR174*,*SLAMF7*,*WIF1*,*CTSW*,*CHIT1*,*CPA3*,*BMP1*,*EGR3*,*CX3CR1*,*EGR1*,*TREM2*,*ATF3*,*ICAM4*,*C8B*,*NR4A3*,*CCL8*,*HAS2*,*C4BPA*,*ITGB6*,*HBEGF*,*AGTR2*,*SERPIND1*,*CEACAM5*,*SFRP2*,*SELE*,*HLA‐DRB1*,*HLA‐DRB5*,*FGG*
  Down‐regulated (77 genes)   *IL1R2*,*CEACAM4*,*ST6GALNAC3*,*ITGA10*,*MERTK*,*FKBP5*,*CLEC4E*,*LAMB1*,*MGAM*,*RPS6KA2*,*FLT1*,*IRAK3*,*SULT1B1*,*AOX1*,*SH3PXD2B*,*RNASE2*,*IL18R1*,*CD163*,*IL1RL1*,*GRASP*,*MT1A*,*S100A12*,*MMP8*,*GLT1D1*,*TMTC1*,*S100A8*,*IL4R*,*IL18RAP*,*FLT3*,*ANPEP*,*MT1M*,*SIGLEC10*,*SPARCL1*,*SMAP2*,*TIMP4*,*ANGPTL1*,*HIF3A*,*PKHD1L1*,*LILRB3*,*FPR1*,*SLED1*,*LDLRAD3*,*FAM150B*,*FPR2*,*ZBTB16*,*GCA*,*ARG1*,*CXCR2P1*,*S100A9*,*TMEM204*,*TINAGL1*,*ABCC8*,*VCAN*,*APOLD1*,*DDIT4*,*ARRDC2*,*SERPINA3*,*PIK3R3*,*ADM*,*PNMT*,*BTNL9*,*CRISPLD2*,*SLCO2A1*,*VNN2*,*TUBB1*,*PSAT1*,*PPBP*,*DEFA4*,*AQP9*,*TTN*,*PDK4*,*MT1L*,*MT1X*,*ORM1*,*CHRM2*,*PTX3*,*EIF1AY*
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###### 

Screening 139 DEGs in COPD by integrated microarray. AveExpr, average expression; FDR, false discovery rate

  Gene symbol    logFC          AveExpr       *t*            *P*‐value     FDR
  -------------- -------------- ------------- -------------- ------------- -------------
  *IL1R2*        −3.724170635   4.910345092   −14.57070196   5.24E−25      8.38E−21
  *CEACAM4*      −1.546190038   3.289938835   −14.11578934   3.65E−24      2.92E−20
  *ST6GALNAC3*   −1.509348297   4.115922297   −13.72934365   1.93E−23      1.03E−19
  *ITGA10*       −1.304452408   4.156071544   −13.3424854    1.05E−22      4.18E−19
  *MERTK*        −1.371100619   5.743922084   −13.22669655   1.74E−22      4.99E−19
  *FKBP5*        −2.553152066   5.964790869   −13.21010646   1.87E−22      4.99E−19
  *CLEC4E*       −2.102592383   3.712865442   −12.2724444    1.22E−20      2.44E−17
  *LAMB1*        −1.236900341   6.51036255    −12.11282186   2.51E−20      4.31E−17
  *MGAM*         −1.918275604   3.743487329   −12.0971852    2.69E−20      4.31E−17
  *RPS6KA2*      −1.051171425   6.235125074   −11.99287281   4.32E−20      6.28E−17
  *FLT1*         −1.43735859    5.302047032   −11.6588263    1.98E−19      2.43E−16
  *IRAK3*        −1.440362949   5.407265256   −11.53504535   3.48E−19      3.71E−16
  *PIEZO2*       1.165120322    5.154801689   11.4846069     4.38E−19      4.38E−16
  *SULT1B1*      −1.966128566   3.712292447   −11.44142282   5.34E−19      5.02E−16
  *AOX1*         −1.498003567   4.380016656   −10.80239392   1.02E−17      8.14E−15
  *SH3PXD2B*     −1.360072374   4.796109196   −10.45348254   5.15E−17      3.92E−14
  *RNASE2*       −2.214352488   3.502846585   −10.41707921   6.11E−17      4.44E−14
  *IL18R1*       −1.552709013   4.479557525   −10.21566115   1.56E−16      1.04E−13
  *CD163*        −2.353331128   6.483508901   −10.18905044   1.77E−16      1.13E−13
  *IL1RL1*       −2.008254697   5.747865421   −10.06701534   3.13E−16      1.88E−13
  *INHBA*        1.437565757    4.698423572   10.06451042    3.17E−16      1.88E−13
  *VCAM1*        1.58323448     4.54949487    9.975765691    4.80E−16      2.74E−13
  *GRASP*        −1.019125221   5.351837423   −9.953904434   5.32E−16      2.93E−13
  *RSPO2*        1.22508185     4.281279622   9.943524241    5.59E−16      2.98E−13
  *CD1C*         1.320908918    4.048138575   9.847836259    8.75E−16      4.51E−13
  *HSD17B6*      1.611303762    5.543589418   9.811225763    1.04E−15      5.03E−13
  *MT1A*         −2.003809136   5.341700669   −9.802106469   1.08E−15      5.10E−13
  *AQP3*         1.465444106    6.255672988   9.709215286    1.68E−15      7.66E−13
  *S100A12*      −2.381911789   3.793860618   −9.658062064   2.13E−15      9.26E−13
  *APLNR*        1.462761779    4.060794485   9.514044214    4.19E−15      1.76E−12
  *GPD1*         1.162408188    4.425391991   9.418745073    6.56E−15      2.65E−12
  *EGR2*         1.7756242      5.312493191   9.415498145    6.66E−15      2.65E−12
  *MMP8*         −1.963376342   1.850422771   −9.410996945   6.80E−15      2.65E−12
  *KCNA3*        1.127720579    5.181587794   9.376872801    7.99E−15      2.98E−12
  *SLC18A2*      1.155076678    4.861252305   9.375465524    8.04E−15      2.98E−12
  *GLT1D1*       −1.354253187   4.134707596   −9.333414043   9.80E−15      3.33E−12
  *TMTC1*        −1.221922174   4.907718006   −9.2268097     1.62E−14      5.28E−12
  *S100A8*       −1.984436486   6.732435285   −9.226677546   1.62E−14      5.28E−12
  *IL4R*         −1.016737627   6.13438495    −9.220088063   1.67E−14      5.34E−12
  *IL18RAP*      −1.20706302    4.403623117   −9.181902429   2.00E−14      6.26E−12
  *FRZB*         1.108947075    4.570621342   9.054280215    3.64E−14      1.08E−11
  *PTGS2*        1.909599543    5.385732252   9.037623232    3.94E−14      1.14E−11
  *FLT3*         −1.068728329   2.955444457   −9.011875495   4.44E−14      1.24E−11
  *OLR1*         1.516024757    5.630156756   9.006280553    4.56E−14      1.24E−11
  *ANPEP*        −1.451754311   4.687966342   −9.001861447   4.66E−14      1.24E−11
  *MT1M*         −2.585708871   5.454959847   −8.990902454   4.90E−14      1.29E−11
  *SIGLEC10*     −1.464287775   4.29164058    −8.960779525   5.65E−14      1.46E−11
  *EDNRA*        1.016233852    5.691095587   8.939250683    6.25E−14      1.56E−11
  *SHISA2*       1.00660372     5.288052754   8.886393339    8.02E−14      1.94E−11
  *SPARCL1*      −1.096814178   7.567105051   −8.760826399   1.45E−13      3.30E−11
  *SMAP2*        −1.030733342   6.515681918   −8.593715399   3.17E−13      6.73E−11
  *TIMP4*        −1.656076369   4.229601784   −8.456527093   6.04E−13      1.19E−10
  *ELF5*         1.521617319    4.673219557   8.448782695    6.26E−13      1.21E−10
  *ANGPTL1*      −1.111036176   3.340161894   −8.413321275   7.39E−13      1.37E−10
  *HIF3A*        −1.065614158   4.526630285   −8.386705336   8.38E−13      1.52E−10
  *PKHD1L1*      −1.402091953   3.533210448   −8.281317436   1.37E−12      2.29E−10
  *LUM*          1.008125744    6.388824425   8.261829056    1.50E−12      2.45E−10
  *CYSLTR1*      1.017621995    4.334713339   8.231060286    1.74E−12      2.78E−10
  *LILRB3*       −1.182035723   3.930324211   −8.201110624   2.00E−12      3.11E−10
  *FPR1*         −1.497358339   5.123265733   −8.165184027   2.36E−12      3.63E−10
  *BMP5*         1.082572       4.856866963   8.039056504    4.26E−12      6.14E−10
  *HPGDS*        1.178976758    4.9661482     7.971057179    5.85E−12      8.07E−10
  *SLED1*        −1.418643068   4.176703046   −7.93529438    6.92E−12      9.42E−10
  *MS4A2*        1.127545704    4.501069641   7.934255426    6.95E−12      9.42E−10
  *DCC*          1.107054924    4.066396917   7.874112823    9.20E−12      1.21E−9
  *LDLRAD3*      −1.132183539   4.777010972   −7.827670594   1.14E−11      1.42E−9
  *FAM150B*      −1.326763929   3.661484534   −7.801467295   1.29E−11      1.57E−9
  *FOSB*         2.16754811     6.605909434   7.722677313    1.86E−11      2.20E−9
  *FPR2*         −1.585779616   4.015151074   −7.702560188   2.04E−11      2.40E−9
  *ZBTB16*       −1.704030574   5.808698383   −7.660799671   2.48E−11      2.87E−9
  *GCA*          −1.036962474   4.831056628   −7.646120016   2.65E−11      3.03E−9
  *HHIP*         1.361681455    6.338309941   7.624501498    2.93E−11      3.28E−9
  *CD200*        1.045448111    4.105658515   7.579848564    3.61E−11      3.95E−9
  *ARG1*         −1.363394352   2.024018729   −7.54254425    4.29E−11      4.60E−9
  *AMPD1*        1.043721979    3.103940463   7.443735113    6.77E−11      6.85E−9
  *ICOS*         1.222541378    4.277643563   7.41874473     7.59E−11      7.59E−9
  *CXCR2P1*      −1.15616615    4.439580145   −7.399724607   8.29E−11      8.23E−9
  *S100A9*       −1.545635339   5.747693368   −7.378920244   9.12E−11      9.01E−9
  *RTKN2*        1.696929199    6.166705232   7.344341435    1.07E−10      1.03E−8
  *TMEM204*      −1.048529786   6.26406167    −7.165974961   2.43E−10      2.11E−8
  *CD83*         1.134658456    5.71435664    7.163495775    2.45E−10      2.12E−8
  *FABP4*        1.58545563     4.778254935   7.12319994     2.95E−10      2.51E−8
  *TINAGL1*      −1.026326535   5.532226715   −7.093847539   3.38E−10      2.84E−8
  *ABCC8*        −1.278473261   3.740007718   −7.069781506   3.77E−10      3.09E−8
  *VCAN*         −1.162194417   5.676393323   −7.050563618   4.11E−10      3.29E−8
  *ISLR*         1.017944512    5.018753667   7.010420181    4.94E−10      3.80E−8
  *APOLD1*       −1.385170588   5.098238511   −6.976021904   5.78E−10      4.35E−8
  *DDIT4*        −1.34772118    5.257280573   −6.808572358   1.23E−9       8.33E−8
  *ARRDC2*       −1.061269085   5.499220509   −6.762488227   1.52E−9       1.01E−7
  *GPR174*       1.391314128    4.486280437   6.747714106    1.63E−9       1.07E−7
  *SERPINA3*     −1.612709918   5.391772667   −6.745585747   1.64E−9       1.07E−7
  *PIK3R3*       −1.190376757   5.660292101   −6.728449631   1.77E−9       1.14E−7
  *SLAMF7*       1.083604552    4.392800911   6.727219831    1.78E−9       1.14E−7
  *WIF1*         1.237156067    6.258872842   6.708747667    1.94E−9       1.24E−7
  *ADM*          −1.075662424   5.196278444   −6.701236397   2.00E−9       1.28E−7
  *PNMT*         −1.051631588   4.068574241   −6.553848929   3.88E−9       2.30E−7
  *CTSW*         1.07957302     4.747480058   6.545368949    4.04E−9       2.38E−7
  *BTNL9*        −1.132836349   5.578696855   −6.494296937   5.07E−9       2.82E−7
  *CHIT1*        1.774209888    5.594573377   6.490067624    5.17E−9       2.87E−7
  *CRISPLD2*     −1.078448778   5.7156417     −6.459148182   5.93E−9       3.26E−7
  *CPA3*         1.002710147    5.278769406   6.398904433    7.75E−9       4.12E−7
  *BMP1*         1.049814522    5.450758141   6.3426456      9.95E−9       5.12E−7
  *SLCO2A1*      −1.051736858   6.743524273   −6.312993603   1.13E−8       5.69E−7
  *VNN2*         −1.015536891   4.57616008    −6.274690529   1.34E−8       6.55E−7
  *TUBB1*        −1.110536854   3.804924924   −6.264199999   1.41E−8       6.82E−7
  *PSAT1*        −1.190066031   3.005323949   −6.258737184   1.44E−8       6.94E−7
  *EGR3*         1.186935902    4.097335491   6.248573488    1.51E−8       7.22E−7
  *CX3CR1*       1.284828947    5.212105592   6.144966898    2.38E−8       1.08E−6
  *EGR1*         1.194905541    7.538328018   6.08564001     3.08E−8       1.35E−6
  *TREM2*        1.128703086    3.987081843   6.03163178     3.90E−8       1.67E−6
  *ATF3*         1.034162475    4.884273698   5.696410877    1.65E−7       5.92E−6
  *PPBP*         −1.424569764   3.860588827   −5.646955582   2.04E−7       7.16E−6
  *ICAM4*        1.390911425    5.019641081   5.625030952    2.24E−7       7.74E−6
  *DEFA4*        −1.206319405   2.718323142   −5.614366702   2.34E−7       8.06E−6
  *C8B*          1.199289417    3.724442441   5.595043977    2.54E−7       8.65E−6
  *NR4A3*        1.153028606    4.646253713   5.56155394     2.93E−7       9.79E−6
  *CCL8*         1.533954481    3.932933151   5.448623389    4.71E−7       1.48E−5
  *AQP9*         −1.182290805   4.835881555   −5.430616006   5.08E−7       1.56E−5
  *HAS2*         1.525864945    3.562127425   5.306311934    8.51E−7       2.44E−5
  *TTN*          −1.043207507   3.817413024   −5.293238479   8.98E−7       2.56E−5
  *C4BPA*        1.055176798    7.356691544   5.268476209    9.95E−7       2.79E−5
  *ITGB6*        1.140444449    6.076736655   5.260091655    1.03E−6       2.86E−5
  *PDK4*         −1.021408815   6.733080202   −5.134267178   1.72E−6       4.47E−5
  *HBEGF*        1.032852155    5.680806271   5.061817586    2.31E−6       5.73E−5
  *MT1L*         −1.182918274   2.526143932   −4.990697548   3.08E−6       7.38E−5
  *MT1X*         −1.137570423   3.368378253   −4.974584006   3.29E−6       7.77E−5
  *AGTR2*        1.364930071    3.524442993   4.842112874    5.57E−6       0.000119643
  *ORM1*         −1.331793001   2.918107873   −4.800748967   6.56E−6       0.000138298
  *CHRM2*        −1.011281909   2.379732249   −4.689445874   1.01E−5       0.000200001
  *SERPIND1*     1.253485683    3.227485742   4.600275561    1.43E−5       0.000265554
  *CEACAM5*      1.121861431    3.16229753    4.495719542    2.14E−5       0.000368719
  *SFRP2*        1.129656517    4.14961175    4.486856217    2.21E−5       0.000377179
  *SELE*         1.138034748    3.853029685   3.80214458     0.00026654    0.003035211
  *PTX3*         −1.402248844   4.135304651   −3.574413207   0.000577009   0.005747801
  *HLA‐DRB1*     2.096264176    4.01015487    3.496867141    0.000745469   0.007027456
  *HLA‐DRB5*     2.134896841    3.007061623   3.473802838    0.000803932   0.007481531
  *EIF1AY*       −1.506138016   3.020677733   −3.35747922    0.00117078    0.010029593
  *FGG*          1.286056757    4.918716551   2.965432506    0.003905804   0.026040868
  *MSMB*         1.936339164    3.146192242   2.931036227    0.00432076    0.028265267
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![Hierarchical clustering heatmap of 139 DEGs screened on the basis of \|FC\| \> 1 and a corrected *P* \< 0.05. Red represents the up‐regulated DEGs, and green represents down‐regulated DEGs.](FEB4-9-1880-g002){#feb412719-fig-0002}

![Volcano plots of differential gene expression data between two sets of samples. Red represents the up‐regulated DEGs, and green represents down‐regulated DEGs. adj.,*P*.Val, adjusted *P*‐value.](FEB4-9-1880-g003){#feb412719-fig-0003}

GO enrichment analysis of DEGs {#feb412719-sec-0010}
------------------------------

GO analysis was done on the DEGs against BP, MF and CC terms. Biological annotation of the DEGs with COPD was identified using the [david]{.smallcaps} online analysis tool. As shown in Fig. [4](#feb412719-fig-0004){ref-type="fig"}, GO functional enrichments of the DEGs with a *P*‐value \<0.05 were obtained. Significant results of the GO enrichment analysis of the DEGs associated with COPD were shown in Table [3](#feb412719-tbl-0003){ref-type="table"}. In the BP category, the DEGs were mainly involved in inflammatory response, immune response and response to lipopolysaccharide. In the MF category, the DEGs were mainly enriched in receptor activity and receptor for advanced glycation end products (RAGE) receptor binding. In the CC category, the DEGs were mainly involved in the extracellular region and space, the integral component of the plasma membrane, the plasma membrane and the external side of the plasma membrane (Fig. [5](#feb412719-fig-0005){ref-type="fig"}).

![GO enrichment analysis of DEGs in COPD. GO analysis divided DEGs into three functional groups: BPs, cell composition and MF. Green represents BP category, blue represents cell composition category and red represents MF category.](FEB4-9-1880-g004){#feb412719-fig-0004}

###### 

GO analysis of DEGs associated with COPD

  Term ID      Category   Description                                                                               Count   *P*‐value    Bonferroni
  ------------ ---------- ----------------------------------------------------------------------------------------- ------- ------------ ------------
  GO:0006954   BP         Inflammatory response                                                                     18      9.11E−9      0.0000088
  GO:0006955   BP         Immune response                                                                           18      4.26E−8      0.0000412
  GO:0032496   BP         Response to lipopolysaccharide                                                            9       0.0000513    0.04832
  GO:0002523   BP         Leukocyte migration involved in inflammatory response                                     4       0.0000782    0.072795
  GO:0007155   BP         Cell adhesion                                                                             14      0.0000787    0.073195
  GO:0002576   BP         Platelet degranulation                                                                    7       0.000175     0.155654
  GO:0030198   BP         Extracellular matrix organization                                                         9       0.000178     0.157584
  GO:0050729   BP         Positive regulation of inflammatory response                                              6       0.000292     0.245789
  GO:0006935   BP         Chemotaxis                                                                                7       0.000438     0.344834
  GO:0071294   BP         Cellular response to zinc ion                                                             4       0.000438     0.345355
  GO:0045926   BP         Negative regulation of growth                                                             4       0.000438     0.345355
  GO:0045600   BP         Positive regulation of fat cell differentiation                                           5       0.00053      0.400817
  GO:0050832   BP         Defense response to fungus                                                                4       0.001263     0.705093
  GO:0060326   BP         Cell chemotaxis                                                                           5       0.001801     0.824787
  GO:0030593   BP         Neutrophil chemotaxis                                                                     5       0.001906     0.841641
  GO:0010043   BP         Response to zinc ion                                                                      4       0.002927     0.941058
  GO:0001501   BP         Skeletal system development                                                               6       0.004843     0.990808
  GO:0007165   BP         Signal transduction                                                                       19      0.00503      0.992337
  GO:0002437   BP         Inflammatory response to antigenic stimulus                                               3       0.0062       0.997541
  GO:0030178   BP         Negative regulation of Wnt signaling pathway                                              4       0.008258     0.999668
  GO:0007263   BP         Nitric oxide‐mediated signal transduction                                                 3       0.009889     0.999932
  GO:0071356   BP         Cellular response to tumor necrosis factor                                                5       0.011676     0.999988
  GO:0001666   BP         Response to hypoxia                                                                       6       0.012312     0.999994
  GO:0050776   BP         Regulation of immune response                                                             6       0.014105     0.999999
  GO:0035924   BP         Cellular response to vascular endothelial growth factor stimulus                          3       0.014331     0.999999
  GO:0002035   BP         Brain renin‐angiotensin system                                                            2       0.015897     1
  GO:0070488   BP         Neutrophil aggregation                                                                    2       0.015897     1
  GO:0006952   BP         Defense response                                                                          4       0.016421     1
  GO:0032868   BP         Response to insulin                                                                       4       0.016421     1
  GO:0050900   BP         Leukocyte migration                                                                       5       0.016519     1
  GO:0001816   BP         Cytokine production                                                                       3       0.016818     1
  GO:0035987   BP         Endodermal cell differentiation                                                           3       0.019474     1
  GO:0042476   BP         Odontogenesis                                                                             3       0.019474     1
  GO:0032689   BP         Negative regulation of interferon‐gamma production                                        3       0.020864     1
  GO:0010033   BP         Response to organic substance                                                             3       0.020864     1
  GO:0071549   BP         Cellular response to dexamethasone stimulus                                               3       0.022294     1
  GO:0007204   BP         Positive regulation of cytosolic calcium ion concentration                                5       0.022427     1
  GO:1900625   BP         Positive regulation of monocyte aggregation                                               2       0.023751     1
  GO:2001179   BP         Regulation of interleukin‐10 secretion                                                    2       0.023751     1
  GO:0032602   BP         Chemokine production                                                                      2       0.023751     1
  GO:0070295   BP         Renal water absorption                                                                    2       0.023751     1
  GO:1902042   BP         Negative regulation of extrinsic apoptotic signaling pathway via death domain receptors   3       0.0284       1
  GO:0042742   BP         Defense response to bacterium                                                             5       0.028971     1
  GO:0030307   BP         Positive regulation of cell growth                                                        4       0.029638     1
  GO:0002793   BP         Positive regulation of peptide secretion                                                  2       0.031543     1
  GO:0032673   BP         Regulation of interleukin‐4 production                                                    2       0.031543     1
  GO:0032119   BP         Sequestering of zinc ion                                                                  2       0.031543     1
  GO:0072593   BP         Reactive oxygen species metabolic process                                                 3       0.031676     1
  GO:0018108   BP         Peptidyl‐tyrosine phosphorylation                                                         5       0.034254     1
  GO:0045786   BP         Negative regulation of cell cycle                                                         3       0.035093     1
  GO:0042493   BP         Response to drug                                                                          7       0.03518      1
  GO:0007160   BP         Cell‐matrix adhesion                                                                      4       0.035316     1
  GO:0006953   BP         Acute‐phase response                                                                      3       0.038646     1
  GO:0002381   BP         Immunoglobulin production involved in immunoglobulin‐mediated immune response             2       0.039273     1
  GO:0008285   BP         Negative regulation of cell proliferation                                                 8       0.039604     1
  GO:0043408   BP         Regulation of mitogen‐activated protein kinase cascade                                    3       0.042329     1
  GO:0002548   BP         Monocyte chemotaxis                                                                       3       0.044219     1
  GO:0045429   BP         Positive regulation of nitric oxide biosynthetic process                                  3       0.046139     1
  GO:0010042   BP         Response to manganese ion                                                                 2       0.046942     1
  GO:0038084   BP         Vascular endothelial growth factor signaling pathway                                      2       0.046942     1
  GO:0005576   CC         Extracellular region                                                                      44      2.35E−14     3.22E−12
  GO:0005615   CC         Extracellular space                                                                       40      4.29E−14     5.89E−12
  GO:0005887   CC         Integral component of plasma membrane                                                     32      2.71E−8      0.00000371
  GO:0005886   CC         Plasma membrane                                                                           56      0.00000132   0.000181
  GO:0009897   CC         External side of plasma membrane                                                          10      0.0000284    0.003882
  GO:0031093   CC         Platelet alpha‐granule lumen                                                              5       0.000713     0.093083
  GO:0005578   CC         Proteinaceous extracellular matrix                                                        8       0.003704     0.398509
  GO:0070062   CC         Extracellular exosome                                                                     32      0.011945     0.807247
  GO:0030666   CC         Endocytic vesicle membrane                                                                4       0.012698     0.826358
  GO:0031012   CC         Extracellular matrix                                                                      7       0.02228      0.954358
  GO:0030669   CC         Clathrin‐coated endocytic vesicle membrane                                                3       0.03651      0.993875
  GO:0048471   CC         Perinuclear region of cytoplasm                                                           10      0.039931     0.996238
  GO:0004872   MF         Receptor activity                                                                         10      0.0000321    0.009231
  GO:0050786   MF         RAGE receptor binding                                                                     4       0.0000611    0.017515
  GO:0004908   MF         Interleukin‐1 receptor activity                                                           3       0.001097     0.271869
  GO:0005201   MF         Extracellular matrix structural constituent                                               4       0.013171     0.97833
  GO:0017147   MF         Wnt protein binding                                                                       3       0.02166      0.998215
  GO:0004896   MF         Cytokine receptor activity                                                                3       0.028658     0.999776
  GO:0035662   MF         Toll‐like receptor 4 binding                                                              2       0.029063     0.999801
  GO:0004982   MF         *N*‐formyl peptide receptor activity                                                      2       0.029063     0.999801
  GO:0008201   MF         Heparin binding                                                                           5       0.030385     0.999866
  GO:0008083   MF         Growth factor activity                                                                    5       0.031597     0.999907
  GO:0004714   MF         Transmembrane receptor protein tyrosine kinase activity                                   3       0.031677     0.999909
  GO:0050544   MF         Arachidonic acid binding                                                                  2       0.036196     0.999976
  GO:0005160   MF         Transforming growth factor‐beta receptor binding                                          3       0.03807      0.999987
  GO:0005178   MF         Integrin binding                                                                          4       0.042233     0.999996
  GO:0042803   MF         Protein homodimerization activity                                                         11      0.042565     0.999997
  GO:0004875   MF         Complement receptor activity                                                              2       0.043278     0.999997
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![Distribution of DEGs in COPD for the most significant GO‐enriched functions.](FEB4-9-1880-g005){#feb412719-fig-0005}

KEGG pathway analysis of DEGs {#feb412719-sec-0011}
-----------------------------

We analyzed the DEGs using the KOBAS 3.0 online analysis database. As shown in Table [4](#feb412719-tbl-0004){ref-type="table"}, the DEGs were enriched in 48 pathways, especially hematopoietic cell lineage and cytokine‐cytokine receptor interaction. The genes and pathway nodes are represented by [cytoscape]{.smallcaps} version 3.6.1 software that was used to calculate the topological characteristics of the network and determine each node (Fig. [6](#feb412719-fig-0006){ref-type="fig"}).

###### 

KEGG pathway analysis of DEGs associated with COPD

  ID         Pathway                                                Gene count   Corrected *P*‐value   DEGs
  ---------- ------------------------------------------------------ ------------ --------------------- ----------------------------------------------------------------------------------------------------
  hsa04640   Hematopoietic cell lineage                             7            4.07E−6               *FLT3*,*IL4R*,*HLA‐DRB1*,*HLA‐DRB5*,*IL1R2*,*CD1C*,*ANPEP*
  hsa04060   Cytokine‐cytokine receptor interaction                 10           4.07E−6               *FLT3*,*FLT1*,*CCL8*,*IL4R*,*INHBA*,*CX3CR1*,*IL1R2*,*IL18RAP*,*PPBP*,*IL18R1*
  hsa05150   *Staphylococcus aureus* infection                      5            0.000147              *HLA‐DRB1*,*FPR2*,*FGG*,*FPR1*,*HLA‐DRB5*
  hsa05166   Human T‐lymphotropic virus type 1 infection            8            0.000174              *PIK3R3*,*HLA‐DRB1*,*ATF3*,*HLA‐DRB5*,*VCAM1*,*IL1R2*,*EGR2*,*EGR1*
  hsa05321   Inflammatory bowel disease                             5            0.000174              *HLA‐DRB1*,*IL18RAP*,*IL4R*,*HLA‐DRB5*,*IL18R1*
  hsa04514   Cell adhesion molecules                                6            0.000456              *SELE*,*HLA‐DRB1*,*ICOS*,*HLA‐DRB5*,*VCAM1*,*VCAN*
  hsa04151   Phosphoinositide 3‐kinase‐Akt signaling pathway        8            0.000732              *CHRM2*,*PIK3R3*,*ITGA10*,*IL4R*,*LAMB1*,*DDIT4*,*ITGB6*,*FLT1*
  hsa05146   Amoebiasis                                             5            0.000732              *C8B*,*PIK3R3*,*ARG1*,*LAMB1*,*IL1R2*
  hsa04668   Tumor necrosis factor signaling pathway                5            0.001006              *VCAM1*,*PIK3R3*,*SELE*,*PTGS2*,*IL18R1*
  hsa04080   Neuroactive ligand‐receptor interaction                7            0.00112               *CHRM2*,*FPR2*,*AGTR2*,*APLNR*,*EDNRA*,*CYSLTR1*,*FPR1*
  hsa05200   Pathways in cancer                                     8            0.001401              *DCC*,*FLT3*,*ZBTB16*,*LAMB1*,*PIK3R3*,*HHIP*,*PTGS2*,*EDNRA*
  hsa04614   Renin‐angiotensin system                               3            0.00144               *CPA3*,*AGTR2*,*ANPEP*
  hsa04610   Complement and coagulation cascades                    4            0.002727              *FGG*,*C8B*,*C4BPA*,*SERPIND1*
  hsa05310   Asthma                                                 3            0.003037              *HLA‐DRB1*,*HLA‐DRB5*,*MS4A2*
  hsa00750   Vitamin B~6~ metabolism                                2            0.003805              *PSAT1*,*AOX1*
  hsa05202   Transcriptional misregulation in cancer                5            0.005115              *FLT3*,*ZBTB16*,*FLT1*,*NR4A3*,*IL1R2*
  hsa04933   AGE‐RAGE signaling pathway in diabetic complications   4            0.005115              *VCAM1*,*PIK3R3*,*SELE*,*EGR1*
  hsa04510   Focal adhesion                                         5            0.007653              *PIK3R3*,*ITGA10*,*ITGB6*,*LAMB1*,*FLT1*
  hsa04672   Intestinal immune network for IgA production           3            0.007653              *HLA‐DRB1*,*ICOS*,*HLA‐DRB5*
  hsa05145   Toxoplasmosis                                          4            0.007715              *HLA‐DRB1*,*PIK3R3*,*LAMB1*,*HLA‐DRB5*
  hsa04978   Mineral absorption                                     3            0.007715              *MT1X*,*MT1A*,*MT1M*
  hsa04923   Regulation of lipolysis in adipocytes                  3            0.009035              *PIK3R3*,*PTGS2*,*FABP4*
  hsa05221   Acute myeloid leukemia                                 3            0.009074              *FLT3*,*ZBTB16*,*PIK3R3*
  hsa04380   Osteoclast differentiation                             4            0.009515              *LILRB3*,*PIK3R3*,*FOSB*,*TREM2*
  hsa01100   Metabolic pathways                                     12           0.00997               *PSAT1*,*HPGDS*,*ARG1*,*ST6GALNAC3*,*AOX1*,*PNMT*,*HSD17B6*,*AMPD1*,*PTGS2*,*CHIT1*,*MGAM*,*ANPEP*
  hsa04145   Phagosome                                              4            0.015537              *HLA‐DRB1*,*TUBB1*,*HLA‐DRB5*,*OLR1*
  hsa05140   Leishmaniasis                                          3            0.015831              *HLA‐DRB1*,*PTGS2*,*HLA‐DRB5*
  hsa04512   Extracellular matrix‐receptor interaction              3            0.02016               *ITGA10*,*ITGB6*,*LAMB1*
  hsa05410   Hypertrophic cardiomyopathy                            3            0.02016               *TTN*,*ITGA10*,*ITGB6*
  hsa05222   Small‐cell lung cancer                                 3            0.021463              *PIK3R3*,*PTGS2*,*LAMB1*
  hsa05414   Dilated cardiomyopathy                                 3            0.023455              *TTN*,*ITGA10*,*ITGB6*
  hsa05323   Rheumatoid arthritis                                   3            0.023455              *HLA‐DRB1*,*FLT1*,*HLA‐DRB5*
  hsa04062   Chemokine signaling pathway                            4            0.023572              *CX3CR1*,*PIK3R3*,*CCL8*,*PPBP*
  hsa04915   Estrogen signaling pathway                             3            0.027527              *FKBP5*,*PIK3R3*,*HBEGF*
  hsa04024   cAMP signaling pathway                                 4            0.027527              *CHRM2*,*PIK3R3*,*HHIP*,*EDNRA*
  hsa04810   Regulation of actin cytoskeleton                       4            0.032602              *CHRM2*,*PIK3R3*,*ITGA10*,*ITGB6*
  hsa00350   Tyrosine metabolism                                    2            0.032602              *AOX1*,*PNMT*
  hsa05020   Prion diseases                                         2            0.032602              *C8B*,*EGR1*
  hsa05143   African trypanosomiasis                                2            0.032602              *VCAM1*,*SELE*
  hsa05330   Allograft rejection                                    2            0.038438              *HLA‐DRB1*,*HLA‐DRB5*
  hsa04722   Neurotrophin signaling pathway                         3            0.038438              *IRAK3*,*PIK3R3*,*RPS6KA2*
  hsa05332   Graft‐versus‐host disease                              2            0.042328              *HLA‐DRB1*,*HLA‐DRB5*
  hsa04940   Type I diabetes mellitus                               2            0.04503               *HLA‐DRB1*,*HLA‐DRB5*
  hsa04973   Carbohydrate digestion and absorption                  2            0.047746              *MGAM*,*PIK3R3*
  hsa05322   Systemic lupus erythematosus                           3            0.048708              *HLA‐DRB1*,*C8B*,*HLA‐DRB5*
  hsa04930   Type II diabetes mellitus                              2            0.049139              *ABCC8*,*PIK3R3*
  hsa05144   Malaria                                                2            0.049139              *VCAM1*,*SELE*
  hsa05030   Cocaine addiction                                      2            0.049139              *SLC18A2*,*FOSB*
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![The significant KEGG pathways enrichment of DEGs. Green represents down‐regulated DEGs, blue represents up‐regulated DEGs and red represents the signaling pathway.](FEB4-9-1880-g006){#feb412719-fig-0006}

PPI network analysis of DEGs {#feb412719-sec-0012}
----------------------------

The 139 DEGs were applied for construction of PPI networks using STRING. After removing the discrete and partially connected nodes, the PPI network data of DEGs were imported into the cytoHubba of [cytoscape]{.smallcaps} version 3.6.1, and a complex network of the DEGs was constructed. As shown in Figs [7](#feb412719-fig-0007){ref-type="fig"} and [8](#feb412719-fig-0008){ref-type="fig"}, 14 Hub DEGs were obtained, including *C‐X3‐C motif chemokine receptor 1* (*CX3CR1*), *proplatelet basic protein* (*PPBP*), *prostaglandin‐endoperoxide synthase 2* (*PTGS2*), *formyl peptide receptor 1* (*FPR1*), *formyl peptide receptor 2* (*FPR2*), *vascular cell adhesion molecule 1* (*VCAM1*), *S100 calcium binding protein A12* (*S100A12*), *arginase 1* (*ARG1*), *early growth response 1* (*EGR1*), *CD163*,*fibrinogen gamma chain* (*FGG*), *orosomucoid 1* (*ORM1*), *S100 calcium binding protein A8* (*S100A8*) and *S100 calcium binding protein A9* (*S100A9*).

![PPI network and Hub DEGs. Hub DEGs were identified with [cytoscape]{.smallcaps} version 3.6.1 with cytoHubba plugin, according to the rank of connection degree (number) for each gene, which is represented by the different degrees of color (from red to yellow): the role of the gene is greater in the PPI network with the darker color of the gene. Red, saffron yellow and yellow represent Hub DEGs.](FEB4-9-1880-g007){#feb412719-fig-0007}

![PPI network identified Hub DEGs. Numbers represent connection points of the 14 Hub genes identified by the cytoHubba plugin.](FEB4-9-1880-g008){#feb412719-fig-0008}

[wgcna]{.smallcaps} network construction in lung tissues {#feb412719-sec-0013}
--------------------------------------------------------

A [wgcna]{.smallcaps} network was first constructed using lung tissue expression data from cohorts [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986), independent of COPD status and smoking status (ever/current smoking versus nonsmoking). A total of 2942 DEGs were selected (a corrected *P* \< 0.05) and subsequently used to identify modules of coexpressed genes using a hierarchical clustering procedure. The corresponding branches of the resulting dynamic clustering tree and module are shown as colored bands underneath the cluster tree. We then merged the highly similar dynamic clustering modules into the merged dynamic modules (cut height = 0.25) (Fig. [9](#feb412719-fig-0009){ref-type="fig"}). We identified nine modules ranging in size from 113 genes in the Purple module to 1081 in the Grey module. A module eigengene, a weighted average of the module gene expression profiles, was used to summarize the expression profiles of transcripts in a given module through their first principal component.

![Network construction identifies distinct modules of coexpressed genes. The network was constructed using the lung tissue expression dataset of [GSE27597](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27597) and [GSE106986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106986). The cluster dendrogram was produced by average linkage hierarchical clustering of genes using 1 − topological overlap as dissimilarity measure. Modules (Dynamic Tree Cut) and similarly merged modules (Merged dynamic) of coexpressed genes were assigned colors corresponding to the branches indicated by the horizontal bar beneath the dendrogram (merged cut height = 0.25).](FEB4-9-1880-g009){#feb412719-fig-0009}

Coexpression modules associated with COPD {#feb412719-sec-0014}
-----------------------------------------

To pinpoint modules associated with COPD and smoking status, we analyzed the association of each of the nine module eigengenes with the two traits. As shown in Fig. [10](#feb412719-fig-0010){ref-type="fig"} and Table [5](#feb412719-tbl-0005){ref-type="table"}, all nine modules were significantly correlated with COPD and smoking status. Four modules were negatively associated with COPD and smoking status, marked Tan, Brown, Blue and Cyan, indicating that genes in these modules were predominantly down‐regulated in COPD cases and those who had a history of smoking. However, five modules, in Green yellow, Purple, Black, Red and Grey, were positively associated with COPD cases and smoking status, showing that genes in these modules are predominantly up‐regulated with the traits.

![[wgcna]{.smallcaps} heatmap. Using the default parameter setting and all DEGs (*n* = 2942), we identified nine gene modules using [wgcna]{.smallcaps} that were positively or negatively associated with COPD and smoking trait. Each row corresponds to a module eigengene and each column to a clinical trait (COPD and smoking status). Positive associations are red, and negative associations are green. HCS, history of smoking.](FEB4-9-1880-g010){#feb412719-fig-0010}

###### 

Correlation of module eigengene with COPD and smoking status traits

  [wgcna]{.smallcaps} modules   Gene number   Merged COPD dataset   Smoking status           
  ----------------------------- ------------- --------------------- ---------------- ------- -------
  Tan                           353           −0.69                 8E−13            −0.33   0.002
  Brown                         244           −0.5                  2E−6             −0.36   9E−4
  Blue                          202           −0.54                 1E−7             −0.58   9E−9
  Cyan                          467           −0.61                 1E−9             −0.51   1E−6
  Green yellow                  105           0.58                  9E−9             0.43    5E−5
  Purple                        113           0.57                  2E−8             0.48    5E−6
  Black                         256           0.63                  2E−10            0.51    9E−7
  Red                           121           0.63                  2E−10            0.38    4E−4
  Grey                          1081          0.82                  3E−21            0.67    4E−12
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Four of these nine gene modules, in Cyan, Purple, Red and Grey, attracted our attention in that 14 Hub genes were identified as DEGs from the PPI analysis, including *CX3CR1*,*PPBP*,*PTGS2*,*FPR1*,*FPR2*,*S100A12*,*ARG1*,*EGR1*,*CD163*,*VCAM1*,*FGG*,*ORM1*,*S100A8* and *S100A9*. We calculated gene significance (GS) versus each MM. We found that the 14 Hub genes were also either positively or negatively associated with COPD (Table [6](#feb412719-tbl-0006){ref-type="table"}). *CX3CR1*,*PPBP*,*PTGS2*,*VCAM1*,*S100A12*,*ARG1*,*EGR1*,*CD163*,*S100A8* and *S100A9* were significantly associated with each MM, whereas *FPR1*,*FPR2* and *ORM1* were correlated with each MM except Red MM, and FGG was correlated to each MM except the Purple MM. In addition, we found that the Purple (*CX3CR1*), Red (*EGR1*,*VCAM1* and *PTGS2*) and Grey (*ARG1*,*FGG*, and *PPBP*) genes most significantly correlated with GS for COPD were also the important MM elements (Fig. [11](#feb412719-fig-0011){ref-type="fig"}).

###### 

Fourteen Hub genes positively or negatively associated with COPD and each MM. *P*,*P*‐value for COPD or each MM

  Gene        Located module   GS.COPD        *P* GS.COPD   *P*.MM Cyan   *P*.MM Grey   *P*.MM Purple   *P*.MM Red
  ----------- ---------------- -------------- ------------- ------------- ------------- --------------- ------------
  *CD163*     Cyan             −0.739974023   1.33E−15      4.23E−21      8.88E−10      0.00249         2.57E−5
  *FPR1*      Cyan             −0.662223538   9.25E−12      7.92E−23      5.84E−7       6.61E−5         0.07339
  *FPR2*      Cyan             −0.63983063    7.43E−11      1.37E−21      4.51E−7       6.73E−5         0.07508
  *ORM1*      Cyan             −0.459721444   1.23E−5       3.81E−20      0.00014       0.00196         0.70155
  *S100A12*   Cyan             −0.721577872   1.41E−14      1.50E−14      2.82E−7       4.13E−5         0.00278
  *S100A8*    Cyan             −0.70598989    9.04E−14      6.83E−18      4.01E−7       0.00026         0.01347
  *S100A9*    Cyan             −0.623468037   3.07E−10      7.84E−20      4.68E−6       0.00049         0.04290
  *ARG1*      Grey             −0.632480057   1.42E−10      0.02374       2.47E−10      0.00054         2.19E−9
  *FGG*       Grey             0.304097261    0.00519       0.00646       0.005969      0.2425          3.39E−8
  *PPBP*      Grey             −0.520314885   4.61E−7       5.44E−6       0.001842      0.0388          0.01072
  *CX3CR1*    Purple           0.553212675    5.84E−8       0.00133       9.38E−10      1.81E−13        4.46E−5
  *EGR1*      Red              0.549754835    7.33E−8       0.00127       2.09E−6       0.03903         1.80E−14
  *PTGS2*     Red              0.698684808    2.07E−13      0.00341       2.42E−11      4.99E−5         1.10E−28
  *VCAM1*     Red              0.7344482490   2.75E−15      0.00947       2.66E−12      5.70E−13        3.14E−16
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![COPD absolute GS versus MM. [wgcna]{.smallcaps} calculation of GS to COPD versus MM. In oversimplified terms, MM is a measure of how 'tight' genes cluster within the module, or mathematically, how close gene expression is to the module eigenvalue. A gene with high MM and GS identifies Hub genes that are both key components to the underlying BP and highly associated with the trait of interest. The GS for COPD was plotted. (A) Cyan represents MM. (B) Grey represents MM. (C) Purple represents MM. (D) Red represents MM.](FEB4-9-1880-g011){#feb412719-fig-0011}

Discussion {#feb412719-sec-0015}
==========

In this study, we performed an integrated analysis on the gene expression profiles from lung tissues with or without COPD, aiming to identify the DEGs and related key signaling pathways for the disease. We identified 139 DEGs, including 62 up‐regulated genes and 77 down‐regulated genes. In addition, GO analysis showed that the 139 DEGs associated with COPD were involved in 60 BPs, 16 MFs and 12 CCs. Among these categories, the most important BPs included inflammatory response, immune response and response to lipopolysaccharide; the most important MFs included receptor activity and RAGE receptor binding; and the most important CCs included extracellular region and space, integral component of plasma membrane, plasma membrane and external side of plasma membrane. This finding accords with the knowledge that COPD is characterized by chronic inflammation in the lung and airways [28](#feb412719-bib-0028){ref-type="ref"}, [29](#feb412719-bib-0029){ref-type="ref"}; immune response mediates the development of COPD caused by the harmful stimuli [30](#feb412719-bib-0030){ref-type="ref"}, [31](#feb412719-bib-0031){ref-type="ref"}, [32](#feb412719-bib-0032){ref-type="ref"}; lipopolysaccharide may lead to increased airway and systemic inflammation, and contribute to the progressive deterioration of lung function [33](#feb412719-bib-0033){ref-type="ref"}, [34](#feb412719-bib-0034){ref-type="ref"}; and RAGE is a 'driving force' for cigarette smoke (CS)‐induced airway inflammation in COPD [35](#feb412719-bib-0035){ref-type="ref"}.

KEGG pathway analysis indicated that 48 pathways corresponded to these DEGs associated with COPD. Two pathways including hematopoietic cell lineage and cytokine‐cytokine receptor interaction were most important. This finding is in line with the results from previous studies [18](#feb412719-bib-0018){ref-type="ref"}, [32](#feb412719-bib-0032){ref-type="ref"}.

The PPI network of proteins encoded by DEGs identified 14 Hub DEGs associated with COPD, including *CX3CR1*,*PPBP*,*PTGS2*,*FPR1*,*FPR2*,*VCAM1*,*S100A12*,*ARG1*,*EGR1*,*CD163*,*FGG*,*ORM1*,*S100A8* and *S100A9*. All of these Hub genes were involved in the most important two BPs, two MFs or five CCs revealed by GO analysis, and were mainly implicated in multiple pathways identified by KEGG analysis in this study. Those results indicate that these Hub DEGs are involved in the development and progression of COPD by playing important biological roles in multiple signaling pathways.

Using [wgcna]{.smallcaps} on the merged expression profile from two cohorts of lung tissues with COPD and healthy controls, we identified a set of gene signatures based on the 14 Hub genes. The increased expression of *CX3CR1*,*FGG*,*EGR1*,*VCAM1* and *PTGS2* is positively associated with COPD, and the underexpression of *PPBP*,*FPR1*,*FPR2*,*S100A12*,*ARG1*,*CD163*,*ORM1*,*S100A8* and *S100A9* is negatively associated with COPD.

*CX3CR1* plays an important role in the development of chronic inflammatory lung diseases, such as COPD and emphysema, by contributing to structural destruction and remodeling. Chemoattractant inflammatory cells releasing *CX3CR1*, such as CD8^−^/CD4, dendritic cells, γδ T lymphocytes, natural killer cells and monocytes/macrophages, may lead to mononuclear cell accumulation in the parenchyma and lung vessel walls, release mediators to induce injury, stimulate proliferation and chemoattractant inflammatory cells [36](#feb412719-bib-0036){ref-type="ref"}. In addition, *CX3CR1* ^+^ mononuclear phagocytes may induce an innate immune response to CS via producing interleukin‐6 and tumor necrosis factor‐α, and contribute to emphysema [37](#feb412719-bib-0037){ref-type="ref"}.

*PTGS2* (*COX‐2*), an important mediator of inflammation, was shown to be involved in inflammation response and associated with COPD pathogenesis [38](#feb412719-bib-0038){ref-type="ref"}, [39](#feb412719-bib-0039){ref-type="ref"}, [40](#feb412719-bib-0040){ref-type="ref"}, [41](#feb412719-bib-0041){ref-type="ref"}. The decreased activity of *PTGS2* may protect smokers against the development of COPD [40](#feb412719-bib-0040){ref-type="ref"}. Furthermore, *FPR1* and *FPR2* were reported to be involved in recruitment and activation of inflammatory cells induced by CS, and play important roles in lung inflammation, injury and the pathogenesis of COPD [42](#feb412719-bib-0042){ref-type="ref"}, [43](#feb412719-bib-0043){ref-type="ref"}, [44](#feb412719-bib-0044){ref-type="ref"}, [45](#feb412719-bib-0045){ref-type="ref"}.

*S100A8*,*S100A9*, and *S100A12* might induce neutrophil and monocyte chemotaxis, adhesion to fibrinogen and diapedesis, and neutrophil migration to inflammatory sites [46](#feb412719-bib-0046){ref-type="ref"}, [47](#feb412719-bib-0047){ref-type="ref"}, and have been identified as key biomarkers in inflammatory diseases including COPD and neutrophil‐dominated infections [35](#feb412719-bib-0035){ref-type="ref"}, [48](#feb412719-bib-0048){ref-type="ref"}, [49](#feb412719-bib-0049){ref-type="ref"}. The mRNA levels of *S100A8*,*S100A9* and *S100A12* may be regulated by RAGE, which was shown to contribute to CS‐induced airway inflammation in COPD [35](#feb412719-bib-0035){ref-type="ref"}. This is consistent with our result in this study that the RAGE pathway including *S100A8*,*S100A9* and *S100A12* is important in the development of COPD.

*EGR1* is an autophagy regulator gene that plays important roles in cellular homeostasis, airway remodeling and control of inflammatory immune response; it is also a significant risk factor for susceptibility to COPD [50](#feb412719-bib-0050){ref-type="ref"}, [51](#feb412719-bib-0051){ref-type="ref"}, [52](#feb412719-bib-0052){ref-type="ref"}. *EGR1* may be induced by CS and involved in proinflammatory mechanisms that are likely associated with the development of COPD [51](#feb412719-bib-0051){ref-type="ref"}, whereas Egr‐1^−/−^ mice were observed to resist CS‐induced autophagy, apoptosis and emphysema [53](#feb412719-bib-0053){ref-type="ref"}. These findings exhibit a critical role for *EGR1* in CS‐induced inflammatory immune response and COPD, and effective inhibition of *EGR1* may attenuate airway remodeling and inflammation associated with the pathology of COPD.

*CD163*, a carefully regulated component of the innate immune response to infection and a macrophage receptor for bacteria, was shown to play important roles in functional pulmonary defense elements and the inflammatory immune response of the respiratory system [54](#feb412719-bib-0054){ref-type="ref"}, [55](#feb412719-bib-0055){ref-type="ref"}. Overexpression of *CD163* on lung alveolar macrophages may be implicated in the pathogenesis of COPD and poor lung function [56](#feb412719-bib-0056){ref-type="ref"}.

*ARG1* was shown to contribute to asthma pathogenesis by inhibiting nitric oxide production, modulating fibrosis, regulating arginine metabolism and inhibiting T cell proliferation, and it involves the initiation of adaptive T helper 2 cell‐mediated allergic lung inflammation by regulating group 2 innate lymphoid cells [57](#feb412719-bib-0057){ref-type="ref"}, [58](#feb412719-bib-0058){ref-type="ref"}, [59](#feb412719-bib-0059){ref-type="ref"}, [60](#feb412719-bib-0060){ref-type="ref"}, whereas *ARG1* ablation in the lung may enhance peripheral lung function but have little effect on airway inflammation [61](#feb412719-bib-0061){ref-type="ref"}. The role of *ARG1* in COPD needs to be studied in the future.

*ORM1* appears to function in regulating the activity of the immune system during the acute‐phase reaction and has been identified as an acute exacerbation of COPD‐specific immunomodulatory mediator [62](#feb412719-bib-0062){ref-type="ref"}. *PPBP* serves as a potent neutrophil chemoattractant and activator, and its elevated expression in the bronchial mucosa might be involved in the pathogenesis of COPD [63](#feb412719-bib-0063){ref-type="ref"}, [64](#feb412719-bib-0064){ref-type="ref"}. In addition, *VCAM1* was shown to express in endothelial cells of atopic asthma cases, but not COPD cases [65](#feb412719-bib-0065){ref-type="ref"}, and present an association with lung function [66](#feb412719-bib-0066){ref-type="ref"}. *FGG* was found to be involved in blast lung injury resistance via promoting tissue‐protective adenosine signaling [67](#feb412719-bib-0067){ref-type="ref"}. In the lung tissues of COPD cases, its mRNA expression was reported to correlate with the burden of particulate matter in total lung and lung parenchyma [68](#feb412719-bib-0068){ref-type="ref"}.

In conclusion, we have identified 139 candidate DEGs associated with the progression of COPD. The results from bioinformatic analysis are in agreement with those from previous cell and animal models and human studies. Our results showed that nine Hub genes, *CX3CR1*,*PTGS2*,*FPR1*,*FPR2*,*S100A12*,*EGR1*,*CD163*,*S100A8* and *S100A9*, potentially mediated inflammation and injury of the lung, and play critical roles in the pathogenesis of COPD. The roles of five Hub genes, including *PPBP*,*ARG1*,*FGG*,*VCAM1* and *ORM1*, identified to be associated with COPD in this study need to be confirmed in the future. These findings could improve our understanding of the underlying molecular mechanisms of COPD and provide us with insights for drug target discovery for the disease.

Conflict of interest {#feb412719-sec-0017}
====================

The authors declare no conflict of interest.

Author contributions {#feb412719-sec-0018}
====================

XK, FY and QW conceived and designed the project. XH and YL acquired the data. XG and ZZ analyzed and interpreted the data. XH and YL wrote the paper.

This work was funded by the National Natural Science Foundation of China (81460007), Natural Science Foundation of Yunnan Province, China (2009CD130), and two funds of the Department of Education Scientific Research of Yunnan Province, China (09C0294 and 2015Z085).
